Cheng Liao

778 Dongfang Road
Dongfang, 200085, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond.

Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond.

Journal: Antibody therapeutics

Published: November 23, 2025

Integrating fab phage and yeast display through seamless transfer of paired heavy- and light-chain libraries for efficient antibody discovery.

Integrating fab phage and yeast display through seamless transfer of paired heavy- and light-chain libraries for efficient antibody discovery.

Journal: Antibody therapeutics

Published: October 29, 2025

Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases.

Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases.

Journal: Journal of inflammation research

Published: February 13, 2025

SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity.

SHR-1806, a robust OX40 agonist to promote T cell-mediated antitumor immunity.

Journal: Cancer biology & therapy

Published: November 15, 2024

SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile.

SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile.

Journal: Molecular cancer therapeutics

Published: November 05, 2024

SDP-LIV1, a Novel and Optimized LIV-1 Antibody-drug Conjugate Demonstrating Superior Anti-Tumor Efficacy and Favorable Safety Profile for Treatment of Solid Tumors.

SDP-LIV1, a Novel and Optimized LIV-1 Antibody-drug Conjugate Demonstrating Superior Anti-Tumor Efficacy and Favorable Safety Profile for Treatment of Solid Tumors.

Journal: Molecular cancer therapeutics

Published: September 08, 2024

Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity.

Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity.

Journal: Molecular cancer therapeutics

Published: August 19, 2024

HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles.

HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles.

Journal: Molecular cancer therapeutics

Published: August 12, 2024

Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases.

Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases.

Journal: Journal of inflammation research

Published: June 11, 2024

EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer.

EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer.

Journal: Frontiers in oncology

Published: May 15, 2024

Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity.

Co-blocking TIGIT and PVRIG Using a Novel Bispecific Antibody Enhances Antitumor Immunity.

Journal: Molecular cancer therapeutics

Published: October 30, 2023

A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells.

A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells.

Journal: Communications biology

Published: May 05, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026